MedPath
Found 65 clinical trials|View Analysis
Sort by:

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2
Not yet recruiting
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
First Posted Date
2024-12-03
Last Posted Date
2024-12-03
Lead Sponsor
Shandong Cancer Hospital and Institute
Target Recruit Count
30
Registration Number
NCT06714266

Tislelizumab Combined with SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

Phase 2
Not yet recruiting
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
HNSCC
Interventions
First Posted Date
2024-11-05
Last Posted Date
2024-11-05
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
24
Registration Number
NCT06673693
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1
Recruiting
Conditions
Fanconi Anemia
Head and Neck Squamous Cell Carcinoma
Interventions
First Posted Date
2024-10-18
Last Posted Date
2024-11-20
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
25
Registration Number
NCT06648096
Locations
🇩🇪

Medizinische Hochschule Hannover, Hannover, Germany

🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Cataluña, Spain

Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma

Not Applicable
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Radiation: Head and Neck Cancers
First Posted Date
2024-10-08
Last Posted Date
2025-01-07
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT06630780
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery

Not Applicable
Recruiting
Conditions
Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Radiation: Conventional radiotherapy
Radiation: Accelerated radiotherapy
First Posted Date
2024-09-23
Last Posted Date
2024-12-27
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
75
Registration Number
NCT06607406
Locations
🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

🇺🇸

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

🇺🇸

Advocate Aurora Radiation Oncology, Milwaukee, Wisconsin, United States

A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Phase 3
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Drug: AK117 in combination with AK112
Drug: Placebo in combination with Pembrolizumab
First Posted Date
2024-09-19
Last Posted Date
2024-11-14
Lead Sponsor
Akeso
Target Recruit Count
510
Registration Number
NCT06601335
Locations
🇨🇳

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

🇨🇳

West China Hospital of Sichuan University, Chengdu, Sichuan, China

A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma

Phase 2
Not yet recruiting
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Drug: MRG003 combined with Pucotenlimab
Drug: MRG003 combined with Pucotenlimab+Cisplatin
First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Lei Liu
Target Recruit Count
30
Registration Number
NCT06530914

Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET

Phase 1
Not yet recruiting
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Diagnostic Test: [18F]-olaparib PET scan
First Posted Date
2024-07-01
Last Posted Date
2025-01-01
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
10
Registration Number
NCT06482307
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2
Recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Biological: LVGN6051 Monoclonal Antibody Injection
Biological: toripalimab Injection
Drug: Paclitaxel injection
First Posted Date
2024-04-22
Last Posted Date
2024-06-27
Lead Sponsor
Lyvgen Biopharma Holdings Limited
Target Recruit Count
64
Registration Number
NCT06378177
Locations
🇨🇳

Anhui Cancer Hospital, Hefei, Anhui, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

🇨🇳

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

and more 13 locations

Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors

Phase 1
Recruiting
Conditions
Urothelial Carcinoma
Renal Cell Carcinoma(RCC)
Head and Neck Squamous Cell Carcinoma(HNSCC)
Non-small Cell Lung Cancer(NSCLC)
Malignant Melanoma
Interventions
Drug: LB-LR1109
First Posted Date
2024-03-27
Last Posted Date
2024-11-05
Lead Sponsor
LG Chem
Target Recruit Count
42
Registration Number
NCT06332755
Locations
🇺🇸

NEXT Oncology, Fairfax, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath